insights_auto
Miks on GNLX tõusnud? 2,40%?
Uurige põhjalikumaltchevron_right
GNLX:NASDAQ
Genelux Corp
2,56 $
arrow_upward
+2,40%(+0,060) 1 p
9. okt, 16:00:01 GMT −4 · USD
search
Kõik sümbolid
| Sümbol | Hind | Muutus | % muutus |
|---|
insights_autoÜksuse GNLX põhistatistika genereerimine…
Ava
2,48 $
Kõrge
2,57 $
Madal
2,47 $
Turu kapit.
115,83 mln
Keskm. maht
275,44 tuh
Maht
154,65 tuh
52 näd kõrgeim
8,54 $
52 näd madalaim
2,29 $
Aktsiatulu
−0,87 $
Beeta
0,59
Käibivad aktsiad
45,24 mln
Töötajate arv
26
Ava
2,48 $
Kõrge
2,57 $
Madal
2,47 $
Turu kapit.
115,83 mln
Keskm. maht
275,44 tuh
Maht
154,65 tuh
52 näd kõrgeim
8,54 $
52 näd madalaim
2,29 $
Aktsiatulu
−0,87 $
Beeta
0,59
Käibivad aktsiad
45,24 mln
Töötajate arv
26
Uudised
Veebiallikatest ja uudistepartneritelt
Barchart.com
·
30 minuti eest
Gold & SP 500 Futures Update 10/11/26
MarketBeat
·
1 tunni eest
Iron Horse Acquisitions II Corp. (NASDAQ:IRHO) Stock Short Interest Report for September
The Globe and Mail
·
1 tunni eest
Prediction: This Brilliant ETF Will Crush the S&P 500 Over the Next 20 Years
Yahoo Finance
·
2 tunni eest
Pokémon Cards Just Crushed Bitcoin, Gold and the S&P 500 With 150% Returns
Profiil
Genelux Corporation is a publicly traded late clinical-stage company developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus, a stable DNA virus with a large engineering capacity.
The core of Genelux’s discovery and development efforts revolves around the company's proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec.
The company is currently entered its pivot Phase 3 study in Platinum resistant/refractory ovarian cancer. Trial design based on VIRO-15 Phase 2 trial which showed independent anti-tumor activity of Olvi-Vec and reversal of platinum resistance in the TME. Wikipedia
Teave üksuse Genelux Corp kohta
Tegevjuht-
Töötajad26
Asutatud2001
PeakontoridWestlake Village, California, Ameerika Ühendriigid
Sektor-
Veebisaitgenelux.com